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Objective: Osteoarthritis (OA) is a debilitating chronic condition requiring long-term treatment of pain
and functional impairment. Our objective was to characterize studies addressing management of OA-
related pain with respect to the breadth of interventions, trial duration and size, outcome measures,
and funding sources.
Design: We identiﬁed studies focused on ‘pain’ and ‘osteoarthritis’ from ClinicalTrals.gov and abstracted
data on study status, sample size, design, funding source, duration, outcomes measured, and in-
terventions evaluated. We examined associations among intervention type, funding source, sample size,
duration, and outcomes measured.
Results:We identiﬁed 287 registered studies, of which 69% investigated pharmacologic interventions, 11%
behavioral interventions, and 5% surgical procedures or devices, while the remainder examined other
types of interventions. Eighty-seven percent evaluated knee OA. The average sample size was 290
subjects and average study duration was 7.4 months, with 52% using durations 3 months and 21% 12
months. Industry funded 64% of studies, either fully or partially. Of 180 completed studies, 139 were
pharmacologic studies. Of these, 34 (24%) posted results to the registry. Among the studies funded by
industry, 60% had durations 3 months as compared with 36% among non-industry funded studies
(P < 0.0001). Behavioral intervention trials tended to be of longer duration than pharmacologic trials and
were less likely to be funded by industry.
Conclusion: Over half of OA pain studies and >80% of those funded by industry used trial durations of less
than 6 months. Future studies should take into consideration the need for long-term pain management
for OA when designing trial protocols.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) affects an estimated 151 million persons
worldwide and nearly 27 million adults in the United States
alone1,2. Roughly one-third of American adults over the age of 65
suffer from OA, with OA of the knee, hand, and hip constituting the
three most common forms of the condition2. Symptomatic knee
OA has emerged as a particularly prevalent and debilitating formR064320, R01 AR064320-01,
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s Research Society International. Pof the disease, becoming the most common form of OA among
persons over the age of 65 as well as a leading cause of disability in
the US2e4. OA also imposes a mounting burden on American
healthcare resources, accounting for more than 974,000 hospital
admissions and $46.6 billion in aggregate healthcare expenses in
20105.
The impact of OA on patients and healthcare systems is inten-
siﬁed by the progressive nature of the disorder and its attendant
chronic pain6,7. Because there is currently no OA treatment that
reverses the course of structural progression, OA management
strategies focus on reduction of OA-related pain and improvement
of functional status8,9. This management approach involves a
sequence of non-pharmacologic, pharmacologic, and surgical
treatment strategies10,11.
Despite the chronic, progressive nature of OA, most studies
evaluating the efﬁcacy of pharmacologic regimens in persons withublished by Elsevier Ltd. All rights reserved.
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year, and many studies report treatment durations of less than 6
months12e14. Published studies of the efﬁcacy of behavioral and
other non-pharmacologic interventions (e.g., physical therapy) are
also frequently conducted over short-term time frames15e18. Pub-
lished data on pharmacologic interventions show substantial but
incomplete pain control and raise concerns about the safety of
commonly-prescribed nonsteroidal anti-inﬂammatory drugs
(NSAIDs), which are associated with serious adverse events such as
gastrointestinal bleeding and perforation8,19e21. Traditionally
regarded as a condition of the elderly, OA is diagnosed at increas-
ingly earlier ages, heightening the tension between the need to
safely manage pain over the long-term and an evidence-base
focused on short-term efﬁcacy22e24.
Several contextual factors may affect the design and outcome of
studies of OA-related pain management. First, many of these
studies are sponsored bymanufacturers of analgesic medications or
other agents. It is well established that funding source may affect
trial ﬁndings and the way these results are reported25,26. Hetero-
geneity of outcome measures also adds to the challenges of trans-
lating results of the studies into interpretable, patient-relevant
metrics that would assist patients and their physicians in shared
decision-making19,27,28.
To address these issues of standardization, compliance with study
protocol, and minimization of bias in trial publications, Congress
mandated the creation of ClinicalTrials.gov, a publically accessible
database of clinical trials. This repository has become the most
established and largest registry of clinical trials worldwide29e31. The
registry serves severalpurposes, including fulﬁllingethicalobligations
to convey research designs and ﬁndings to the scientiﬁc and lay
communities, documenting design features before a trial is conducted
(e.g., primary outcome measure, sample size), permitting the com-
parison of published ﬁndings with original design features, and opti-
mizing resource allocation by reducing the number of duplicate
studies30e33.
We sought to survey the current state of OA-related ongoing
or recently completed clinical studies registered with
ClinicalTrials.gov to portray the landscape of studies on OA pain
management with respect to study design and duration, treat-
ments under investigation, funding sources, and the timeliness of
reporting study ﬁndings to the public. We examined whether
studies funded by industry differ from those funded by govern-
ment, hospitals, and/or foundations with respect to duration,
treatments under study, and study design. These data will help
clinicians, funding agencies, and policymakers both anticipate
potential changes in pain treatment options for persons with OA
as well as identify challenges and gaps in current research that
should be addressed by the next generation of studies on pain
management in OA.
Methods
Study selection
To identify clinical trials evaluating pain management in OA, we
used the national clinical trial registry ClinicalTrials.gov.
ClinicalTrials.gov has over 100,000 trials registered to the website
as of 2010 from approximately 140 countries29e31,34. The two
keywords ‘osteoarthritis’ and ‘pain’ were used to restrict the search
to trials registered on the website that included both terms in their
descriptions of evaluated conditions. Search results were then
abstracted from the website into a database listing each trial along
with its associated data elements, which are deﬁned under Data
elements as well as in Table I. Data abstraction was conducted be-
tween October and November 2012.From the trials returned by our query in ClinicalTrials.gov, we
included only those trials that fulﬁlled the following three inclusion
criteria: (1) OA was listed as either the primary condition or one of
at most two underlying conditions contributing to chronic pain; (2)
trials evaluated the efﬁcacy and/or safety of interventions intended
to manage OA-related pain; and (3) if the efﬁcacy and/or safety of
pain management methods were not addressed, the study had to
focus on understanding the origin or progression of OA-related
pain (observational studies).
We implemented three exclusion criteria. (1) Trials were
excluded if they completed enrollment earlier than 1997 since such
trials may not reﬂect contemporarymanagement. Because the time
period in which subjects were recruited varied widely, the date a
trial completed enrollment was determined to be more pertinent
than the date enrollment commenced. (2) Trials that evaluated
more than two underlying pain-related conditions were not
considered. Such trials investigating OA along with other underly-
ing causes of pain were determined to be too broad in focus to give
an accurate picture of research in OA-related pain. (3) Trials were
excluded if they evaluated pain unrelated to OA. For example, trials
that evaluated pain associated with the interventions themselves
(e.g., pain associated with a speciﬁc surgical procedure) rather than
the impact of these interventions on OA-related pain were deemed
tangential to this analysis.
Data elements
We abstracted the following data elements from the
ClinicalTrials.gov registry: protocol title, ClinicalTrials.gov identiﬁ-
cation number (NCT number), study start and completion dates for
enrollment, joint affected, intervention name and type, study
duration, study design, outcome measures, sample size, funding
source, geographic location of the study, trial recruitment status,
whether or not results were reported in the registry, publications
arising from the results of the trial, and, for those trials examining
pharmacologic interventions, the class of drug used in the study as
well as the method of drug application. Detailed descriptions and
classiﬁcation of each data element are presented in Table I.
The categories for pharmacologic regimen types and details of
study designwere developed by consensus between two coauthors
(JNK, EL). When information on any parameter was not directly
accessible from the ClinicalTrials.gov registry, publications associ-
ated with the trials themselves were used to determine the addi-
tional details of the study protocol. In addition to recording
publication citations listed on ClinicalTrials.gov, publications were
sought using the NCT number of a trial on PubMed (Table I).
We classiﬁed interventions as behavioral, pharmacologic,
surgical/device, and ‘other’. Device interventions included surgical
devices such as implants. Nonsurgical devices (e.g., electromagnetic
therapy) were classiﬁed as ‘other.’ The pharmacologic intervention
category included nutraceuticals as a subcategory.
The pharmacologic interventions were divided in the following
groups: biologics, non-opioid analgesics, inhibitors (such as p38
mitogen-activated protein kinase (MAKP) inhibitors and transient
receptorpotential vanilloid (TRPV) inhibitors),NSAIDs, nutraceuticals,
opioids, steroids, and viscosupplements. For those drugs that could
not be adequately classiﬁed into one of these eight groups, an ‘other’
group was created and further divided into ‘centrally-acting’ (e.g.,
duloxetine) or ‘peripherally-acting’ based on the drug’smechanismof
action. Those pharmacologic interventions that couldnot be classiﬁed
into any of these categories were labeled ‘not otherwise speciﬁed’.
Funding source categories were categorized as industry, the Na-
tional Institutes ofHealth (NIH), other government, academic/clinical
institutions, and foundations. If a study received funding from more
than one type of sponsor, all funding sources and types of funding
Table I
Data parameters of cataloged clinical trials
Parameter Description
Design of trial The design of the study according to allocation of interventions and masking. Studies were speciﬁcally evaluated for whether or not
they were interventional or observational; if interventional, whether they used randomization, and whether the masking type was
open label, single-blind, or double-blind.
Drug application For pharmacologic interventions, the method of application or consumption. Included oral, topical and injection (intraarticular, intradermal,
intravenous, and subcutaneous).
Drug classiﬁcation* For pharmacologic interventions, the class of drug evaluated. Included biologics, non-opioid analgesics, inhibitors (such as p38 MAKP
inhibitors and TRPV inhibitors), NSAIDs, nutraceuticals, opioids, steroids, and viscosupplements. Drugs that could not be classiﬁed into
one of these groups were classiﬁed under the group ‘other’ and further classiﬁed as ‘centrally-acting’ or ‘peripherally-acting’ based on
their mechanism of action, such as the centrally-acting pharmaceutical duloxetine.
Duration of follow-up Anticipated time period over which each enrolled subject would be followed. These time periods included pre- or post-intervention
wash-out or tapering periods and were deﬁned by the latest reported time of follow-up. Duration lengths were entered into the
database as days.
Enrollment Number of participants enrolled in a study.
Funder name Speciﬁc name of the sponsor(s) that provided funding for the study.
Funder type* Sponsors were classiﬁed into one of three categories: (1) industry, (2) academic or clinical institutions, and (3) government entities
(including NIH) or foundations.
Geographic location Country afﬁliated with the study. All countries associated with each trial were entered into the database and divided into the following
three groups for analysis: United States, Europe, and Other. Puerto Rico was included in the United States classiﬁcation.
Intervention name Speciﬁc name of drug, technique, or behavioral intervention investigated. If more than one intervention was evaluated or if another
intervention was used as a control, all interventions described in the trial proﬁle were entered into the database.
Intervention type* Intervention evaluated for OA pain management. Included pharmacologic, behavioral, surgical procedures or devices, and ‘other’
interventions. Pharmacologic interventions included nutraceuticals. Interventions listed as ‘other’ included interventions that could
not be categorized into these four types, such as electrotherapy, acupuncture, and thermal treatments.
Joint The joint affected with OA, such as the knee, hip, or spine.
NCT number Identiﬁcation code for each clinical trial registered with ClinicalTrials.gov, formatted as the letters ‘NCT’ proceeded by an 8-digit number.
Outcome measures The instruments used to measure outcomes related to pain, functionality, and/or quality of life (QOL). Trials that used the Western Ontario
and McMaster Universities Arthritis Index (WOMAC), Knee Osteoarthritis Outcome Scales (KOOS), Knee Society Scale (KSS), or a visual
analogue scale (VAS) were speciﬁcally identiﬁed. All trials measuring pain intensity on a numeric scale were classiﬁed as using VAS. Both
primary and secondary outcome measures related to pain, function, and QOL were entered into the database.
Publications Citations for publications associated with each trial, if available. Publications were additionally sought by looking up the NCT number
of each trial on PubMed.
Recruitment status Indicated whether trials were currently open or closed to recruitment. For those studies open to recruitment, studies were listed as not
yet recruiting, recruiting, enrolling by invitation, or active but not recruiting. For those studies closed to recruitment, studies were listed
as completed, suspended, terminated, or withdrawn.
Results posted Identiﬁed which completed studies ofﬁcially reported having results on ClinicalTrials.gov, not whether or not these studies in fact had
results or publications related to their protocol.
Study completion date Date on which ﬁnal data collection had already or is expected to occur.
Study start date Date on which enrollment to the trial had already or is expected to commence.
Title of trial Protocol title supplied by study investigator.
*The three categorical data parameters of intervention type, funder/sponsor type, and drug classiﬁcation were deﬁned and applied by the investigators in the course of
constructing the database. Further details are described in the body of the manuscript.
E. Losina et al. / Osteoarthritis and Cartilage 21 (2013) 1264e12711266were recorded. ClinicalTrials.gov did not provide data on changes in
funding source over the course of the study nor on the speciﬁc
components of the study that were supported by particular funders.
Data validation
Initially all data were abstracted by one co-author (EED). The
stratiﬁcation of pharmacologic interventions was guided by a
clinician author with a clinical and research focus in OA (JNK). To
ensure data abstraction accuracy, we conducted a validation study
in which a second author (MED) performed an independent data
abstraction for a random 10% of studies. As study duration was
particularly relevant for this analysis, two coauthors (EED, MED)
independently abstracted data on duration from all studies and
compared and resolved any discrepancies.
Using information from the registry on details of the study
design, we created a study design quality index as a summative
measure of two components: randomization and blinding.
Randomizationwas coded as a binary variable (randomized or not).
Blinding was scored from 0 to 2, with 0 corresponding to no
blinding, 1 to single blinding, and 2 to double blinding. The index
varied from 0 if the study was not randomized and not blinded to 3
if the study was randomized and double blinded. Details of the
methodology and quality of study randomization and blinding
were not available in ClinicalTrials.gov and thus were not taken into
account in the design quality index.Data analysis
We ﬁrst performed a descriptive analysis of the distributions of
continuous variables and frequency of categorical variables. We
used the Student t-test to compare study duration and sample size
between industry-supported studies and studies supported by
non-industry sources. We also examined whether certain types of
studies (e.g., pharmacologic) more frequently used industry sup-
port than other types (e.g., behavioral). We constructed multivar-
iate logistic regression analyses to identify study features that were
independently associated with industry funding.We also examined
factors associated with posting results as required by the Food and
Drug Administration for completed pharmacologic studies.
Results
Description of studies
The initial search identiﬁed 324 studies registered at
ClinicalTrials.gov. Thirty-seven studies met one or more of our
exclusion criteria. The remaining 287 studies were used in the
current investigation (Fig. 1). Among them, 198 (69%) focused on
pharmacologic interventions, 31 (11%) on behavioral interventions
and 14 (5%) on surgical/device interventions. Another 44 studies
(15%) were categorized as ‘other,’ including nine that did not pro-
vide sufﬁcient information to categorize. Seventy percent of the
324
287
Excluded:37
 -  OA not listed as inclusion
criteria (7 studies)
-  OA listed as one of more
than two evaluated
conditions (23 studies)
-  Evaluated surgical
techniques unrelated to OA
pain (7 studies)
All search results from
ClinicalTrials.gov
Search terms:
‘Osteoarthritis’ and ‘Pain’
Trials used in
analysis
Behavioral
Interventions
31
Pharmacologic
Interventions
198
Surgical / Device
Interventions
14
Not Listed / Other
Interventions
44
Fig. 1. This ﬁgure depicts the process by which trials were collected from ClinicalTrials.
gov. The initial search results were examined and studies that did not focus on
treatments for OA pain were excluded. The included trials are further separated by the
type of intervention they evaluated: pharmacologic, behavioral, surgical, or other.
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Fig. 2. This ﬁgure shows average clinical trial study duration, stratiﬁed by intervention
type (behavioral, pharmacologic, surgical procedures and devices, or other). Average
duration is reported in months. The 95% CIs are indicated in the graph.
Table II
Description of studies on OA and pain registered in ClinicalTrials.gov
U.S. Europe Other parts
of the world
International
collaborations
Overall*
Trial status
Registered 156 60 46 24 286
Closed 123 46 33 24 226
Completed 96 38 29 17 180
Active, not recruiting 11 4 0 1 16
Enrolling by invitation 1 0 1 0 2
Suspended 1 0 0 0 1
Terminated 13 3 2 6 24
Withdrawn 1 1 1 0 3
Open 33 14 13 0 60
Not yet recruiting 10 1 6 0 17
Recruiting 23 13 7 0 43
Intervention type
Behavioral 26 4 1 0 31
Pharmacologic 104 38 33 22 197
Surgical/devices 2 10 1 1 14
Other 18 7 9 1 35
Not listed 6 1 2 0 9
Funded by industry
Yes 105 36 19 24 184
No 51 24 27 0 102
*Because one study did not have geographic data, only 286 studies were included
in this table.
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used a randomized design. One hundred and eighty studies (63%)
were listed as ‘Completed.’ Of the 60 still listed as ‘Open,’ 43 were
actively recruiting. Among open studies, 30 (50%) investigated
pharmacologic interventions. Quality scores varied, with 16% of
studies having a score of 0 (worst) and 65% a score of 3 (best).
The sample size varied depending on intervention type, with
pharmacologic interventions enrolling a greater number of subjects
(mean enrollment of 281 subjects) compared to behavioral (171
subjects), surgical (114 subjects), and other (115 subjects). The
overall P-value comparing sample size of studies of pharmacologic
interventions (mean 281 subjects) vs those of non-pharmacologic
interventions (138 subjects) was <0.0001. Study duration ranged
widely from 4.2 months on average in pharmacologic studies to 45
months on average in surgical studies (P < 0.0001; Fig. 2).
Outcomes varied widely across studies. A VAS was the most
frequently used measure of pain severity, reported by 68% of
studies, followed by the WOMAC Pain Scale, which was reported in
50% of studies. Fewer than 10% of studies measured pain using
other scales such as the KOOS or KSS. One ormore aspects of quality
of life were ascertained in 33% of studies and functional status in
64%. Behavioral intervention studies were more likely to ascertain
quality of life than studies of other types of interventions (odds
ratio (OR) 2.35, 95% conﬁdence interval (CI): 1.11e4.98). Behavioral
intervention studies were also less likely to use VAS as a measure of
outcome (OR 0.18, 95% CI: 0.08e0.41). Pharmacologic studies were
more likely to use WOMAC (OR 1.98, 95% CI: 1.19e3.30) compared
to non-pharmacologic studies.
Among pharmacologic studies, 51 (26%) studied NSAIDS, 69
(35%) opioids, 19 (10%) novel inhibitors, 19 (10%) nutraceuticals, and
19 (10%) focused on peripherally-acting analgesics. Steroids, non-opioid analgesics, biologics, and viscosupplementation were each
examined by less than 7% of registered studies.
One hundred ﬁfty-six studies (55%) were conducted in the US,
an additional 60 studies (21%) in Europe, and another 46 studies
(16%) in other regions of world. Twenty-four studies were done in
multiple geographic areas. In all geographic areas, more than two-
thirds of studies focused on pharmacologic interventions. Seven-
teen percent of studies conducted in the US focused on behavioral
interventions compared to 7% in Europe and 2% in other parts of the
world. Studies of surgical/device interventions were more promi-
nent in Europe, comprising 17% of studies registered in the region
compared to about 2% in other parts of the world (Table II).Role of funding sources
One hundred sixty-ﬁve studies (57%) were funded solely by
industry, 17 (6%) reported being funded solely by government and
foundation sources, and 63 studies (22%) reported clinical and ac-
ademic institutions as funding sources. The rest of the studies re-
ported multiple sources of funding. Among pharmacologic studies,
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303 vs 176, P¼ 0.0187) and shorter (3.6 months average duration vs
7.3 months, P < 0.0001) than those not funded by industry
(Table III). Studies funded by industry tended to have higher quality
index scores, with a mean quality index of 2.4 (out of 3.0) compared
to 2.0 for non-industry funded studies. This difference in method-
ological rigor between industry and non-industry funded studies
diminished when looking only at pharmacologic studies, which
tended to have higher quality index scores overall compared to
non-pharmacologic studies (mean quality index of 2.6 for phar-
macologic studies vs 1.6 for non-pharmacologic, P < 0.0001).
Accordingly, the subset of industry and non-industry funded
pharmacologic studies had similar mean quality scores of 2.5 and
2.6, respectively (Table III). Because there was very little difference
between the quality scores of industry and non-industry funded
pharmacological trials, this stratiﬁed analysis indicated that the
overall higher quality of industry funded studies was confounded
by study type.
Results of multivariate analyses revealed that pharmacologic
studies funded by industry weremore likely than studies funded by
non-industry sources to: be conducted in the US (adjusted OR 9.06,
95% CI: 2.78e29.58), investigate opioids either as active treatment
or comparator (OR 23.79, 95% CI: 4.15e136.50), and use WOMAC to
measure outcomes (OR 8.58, 95% CI: 2.64e27.91). Further, these
analyses showed that industry funded studies were less likely to
measure quality of life (OR 0.20, 95% CI: 0.06e0.65) andmore likely
to be of short duration (3months as compared to>12months, OR
24.18, 95% CI: 4.13e141.41).
Factors associated with posting results
One hundred eighty studies had status ‘Closed: Completed’.
Only 34 of these closed and completed studies (19%) had results
posted. All completed studies that had results posted were fundedTable III
Description of pharmacologic studies by funding source
Funded by industry Yes
n ¼ 165
% No
n ¼ 33
% P value
Status 0.0016
Closed
Completed 121 73% 18 55%
Active, not recruiting 3 2% 2 6%
Enrolling by invitation 0 0% 1 3%
Suspended 1 1% 0 0%
Terminated 21 13% 1 3%
Open
Recruiting 14 8% 6 18%
Not yet recruiting 5 3% 5 15%
Duration 0.0004
Less than 3 months 99 63% 10 30%
3e6 Months 39 25% 10 30%
6e12 Months 4 3% 4 12%
Greater than 12 months 15 10% 9 27%
Design
Randomized 139 85% 32 97% 0.0670
Enrollment mean (SDy) 303 (276) 176 (306) 0.0187
Quality score mean (SDy) 2.5 (1.0) 2.6 (0.8) 0.6506
Focus of study
Novel compounds* 35 21% 9 27% 0.4457
NSAIDs 45 27% 6 18% 0.2769
Opioids 66 40% 3 9% 0.0007
Outcomes
VAS 129 78% 19 58% 0.0131
WOMAC 98 59% 11 33% 0.0061
KOOS 2 1% 5 15% <0.0001
QOL 47 28% 15 45% 0.0556
*Includes novel inhibitors, biologics, and centrally- or peripherally-acting
compounds.
ySD refers to standard deviation.by industry. Furthermore, none of the behavioral studies have had
their results posted. Among 121 pharmacologic industry funded
studies that had been completed, only 34 (28%) had results posted
directly to the registry.
Discussion
Pain management is a paramount priority for patients with OA
and their clinicians35,36. In an attempt to anticipate the pipeline of
pain management interventions currently under study, we exam-
ined features of ongoing studies of OA pain management as re-
ﬂected in the ClinicalTrials.gov repository. Our ﬁndings indicate
that despite the fact that OA pain management poses a decades-
long challenge for each patient with OA and his or her provider,
80% of trials of pain management interventions are less than one
year in duration and half are three months or less. Industry funded
trials are especially likely to be of short duration.
Few systematic evaluations of the methodology of OA-related
research have been reported previously. Three studies published
since 2001 have examined speciﬁc methodological aspects of
research focused on managing OA-related pain37e39. Two of these
studies focused speciﬁcally on the challenge of interpreting the
clinical relevance of study results. Farrar et al. evaluated the 11-
point numerical rating scale as an outcome measure used to mea-
sure pain and pain efﬁcacy and called for standardization of pain
outcome measures across research studies in order to improve the
clinical relevance of OA-related research overall38. Moore et al.
conducted a meta-analysis of randomized control trials investi-
gating the efﬁcacy of NSAIDs39. These authors also focused on the
duration of the trials, noting that while NSAIDs are intended for
long-term use in the treatment of OA-related pain, studies of these
agents in OA were generally conducted over 12 weeks. Boutron
et al. focused on methodological differences between non-
pharmacologic and pharmacologic interventions, noting (as we
did) that pharmacologic studies had greater methodological rigor
as they were more likely to be controlled, randomized, and single-
or double-blinded37. The role of funding source in the development
of pain control interventions has been described in published
literature, most notably in studies evaluating the efﬁcacy of
glucosamine and chondroitin. Vlad et al. and Wandel et al. con-
ducted meta-analyses that examined the sources of funding for
trials investigating glucosamine or chondroitin in the treatment of
OA, observing that studies supported by industry frequently re-
ported greater effect sizes for both drugs in the reduction of pain
than studies without industry support25,26.
Guidelines and recommendations fromprofessional organizations
such as Osteoarthritis Research Society International (OARSI) consti-
tute another segment of the published literature focused on exam-
ining and improving methods in OA-related research10,11,27,28,40e44.
Indeed, OARSI, the American College of Rheumatology (ACR), the
European League of Associations of Rheumatology (EULAR), and the
Initiative onMethods, Measurement, and Pain Assessment in Clinical
Trials (IMMPACT) have each issued recommendations or reports
indicating how researchers should conduct OA-related studies. These
evaluations have generally pointed out that validating and standard-
izing outcome measures might improve the clinical applicability of
trials of OA pain management28,40,42,44. While these reports typically
used outcome measures that examine pain, functional ability, and
patient global assessments, these publications also noted the need for
better, validatedoutcomemeasures toexaminequalityof life28,40,42,44.
The richClinicalTrials.govdatabasecomprisesakeystrengthof this
study, as the database provides insight into therapies in the pipeline
and documents key study characteristics such as funding source and
various design features. As themost extensive and established clinical
trial registry available, ClinicalTrials.gov is used increasingly by
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However, the database also imposes limitations that should be
considered in interpreting our ﬁndings. First, we do not know what
proportion of all studies of OA painmanagement are in fact registered
on ClinicalTrials.gov, nor whether there are systematic differences
between registered and unregistered trials. Similarly, by restricting
our search terms to ‘osteoarthritis’ and ‘pain’, several relevant studies
may have been overlooked. Before any data abstraction, an initial
search was conducted using only the term ‘osteoarthritis,’ yielding
over 1,300 studies in the search results. In order tomaintain a focus on
painmanagement in OA, we limited the ﬁnal search in the registry to
those taggedwith the terms ‘osteoarthritis’ and ‘pain.’ Becausewe do
not know how thoroughly or consistently studies in the database are
tagged with these descriptors, it is possible that we excluded studies
that would have been relevant to our analysis.
Because information for trial proﬁles is provided directly by the
trial investigators, we also do not know how compliant in-
vestigators are with requests to update their listings in
ClinicalTrials.gov regularly30,34. For example, only 19% of studies
listed as closed and completed had posted study ﬁndings to the
registry. We cannot distinguish whether the other studies had not
analyzed their data or simply had not posted the results. Moreover,
registry data are not scrutinized for accuracy. Investigators may
make errors in creating their trial listings on ClinicalTrials.gov,
though the resulting misclassiﬁcation is likely non-differential with
respect to the hypotheses addressed in this paper. Finally, the
sparse detail provided by the ClinicalTrials.gov registry and pro-
tocols limited our understanding of the nature of these study pa-
rameters. For example, study proﬁles clearly stated whether or not
a trial was funded by industry and clearly indicated whether or not
a trial was randomized or observational in nature. However, pro-
tocols gave no indication about the point at which studies became
funded by a particular source or what proportion of funding was
derived from each source. Similarly, protocols listing a trial as
double-blinded and randomized did not provide information on
how randomization was conducted or blinding ensured. Because
protocol parameters were typically described in this binary fashion
(that is, a trial either possessed a certain characteristic or did not),
we accepted the meaning of these parameters at face value.
We conclude that while the pipeline contains a wide range of
interventions for pain management in OA, the studies of these
therapies are generally performed over short time frames. The trial
ﬁndings will therefore be difﬁcult to apply to long-term pain
management strategies39. Industry funded studies are particularly
likely to focus on the short term. These ﬁndings reveal a tension
between the design of research studies and the needs of patients
attempting to effectively manage a chronic disease. Indeed, the
trends described here suggest that many questions about long-
term pain management for patients with OA will not be
addressed fully by the generation of studies currently underway.
The implications for researchers, methodologists, and policy-
makers are clear: in order to attend to the needs and concerns of
patients and their physicians, designing trials that better reﬂect the
patient experience may be an effective next step. The shorter trial
durations typical of studies underway reﬂect funders’ logical im-
pulse to limit investment in the development of any particular
therapeutic agent. As long as regulatory agencies require evidence
of short-term efﬁcacy for approval, industry will not be incented to
conduct the longer-term studies that would capture the challenges
experienced by patients with chronic disease.
Our work accordingly underscores the utility of alternative
research methodologies in addressing the unique problems asso-
ciated with long-term pain management. Pragmatic randomized
controlled trials are one methodologic strategy that inherently
emphasizes the use of real-world clinical settings within a trial inorder to produce outcomes with direct clinical relevance for pa-
tients and their healthcare providers45. Researchers may also
employ observational cohort or case-controlled studies in order to
gain different insights into effective ways to manage pain in ‘real-
world’ clinical settings46. Researchers may alsomake use of entirely
different methodological paradigms such as computer simulation
modeling, which enables researchers to extend the ﬁndings of
short-term studies to long-term patient care47.
Themethods noted above are but a subset of a broad and diverse
array of research methodologies that may permit researchers to
engage the challenges posed by studies of chronic disease. Through
the identiﬁcation of current limitations in the body of OA research
and the judicious use of alternative research approaches to
comprehensively evaluate OA pain management, researchers, pol-
icymakers, and clinicians may be better able to optimize patient
care.
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